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The Ki-67 labelling index is significant for the management of breast cancer. However, the
concordance of Ki-67 expression between preoperative biopsy and postoperative surgical
specimens has not been well evaluated. This study aimed to find the correlation in Ki-67
expression between biopsy and surgical specimens and to determine the clinicopathologi-
cal risk factors associated with discordant values.
Patients and Methods
Ki-67 levels were immunohistochemically measured using paired biopsy and surgical speci-
mens in 310 breast cancer patients between 2008 and 2013. ΔKi-67 was calculated by
postoperative Ki-67 minus preoperative levels. The outliers of ΔKi-67 were defined as
[lower quartile of ΔKi-67–1.5 × interquartile range (IQR)] or (upper quartile + 1.5 × IQR) and
were evaluated according to clinicopathological parameters by logistic regression analysis.
Results
The median preoperative and postoperative Ki-67 levels were 10 (IQR, 15) and 10 (IQR,
25), respectively. Correlation of Ki-67 levels between the two specimens indicated a moder-
ately positive relationship (coefficient = 0.676). Of 310 patients, 44 (14.2%) showed outliers
of ΔKi-67 (range,-20 or28). A significant association with poor prognostic factors was
found among these patients. Multivariate analysis determined that significant risk factors for
outliers of ΔKi-67 were tumor size >1 cm, negative progesterone receptor (PR) expression,
grade III cancer, and age35 years. Among 171 patients with luminal human epidermal
growth factor receptor 2-negative tumors, breast cancer subtype according to preoperative
or postoperative Ki-67 levels discordantly changed in 46 (26.9%) patients and a significant
proportion of patients with discordant cases had1 risk factor.
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Conclusion
Ki-67 expression showed a substantial concordance between biopsy and surgical speci-
mens. Extremely discordant Ki-67 levels may be associated with aggressive tumor biology.
In patients with luminal subtype disease, clinical application of Ki-67 values should be cau-
tious considering types of specimens and clinicopathological risk factors.
Introduction
Ki-67 is of clinical interest for potential uses in the management of breast cancer patients [1]. It
is informative for classification of breast cancer subtypes, may play a predictive role, and is use-
ful in monitoring the response to neoadjuvant therapy [2,3]. At the 13th St. Gallen Interna-
tional Breast Cancer Conference 2013, most of the panel agreed that Ki-67 could be a surrogate
marker for the discrimination between luminal A-like and luminal B-like tumors [4]. Although
Ki-67 levels of<14% were well correlated with the results of the gene expression analysis, a
clear cutoff point for the Ki-67 level for the definition of luminal A or B subtype was not sug-
gested and quality-assured laboratory specific values should be used [4,5].
Clinically, Ki-67 is measured by immunohistochemistry using the MIB-1 antibody. In 2007,
the American Society of Clinical Oncology (ASCO) updated its recommendations for the use
of tumor markers in breast cancer and pointed out that immunohistochemically detected pro-
liferation markers including Ki-67 should not be recommended for clinical practice because of
an insufficient level of evidence and a lack of standardization of assay reagents, procedures,
and scoring [6]. Similar to other immunohistochemically detected biomarkers, the measure-
ment of Ki-67 by immunohistochemistry has methodological variability regarding preanalyti-
cal, analytical, and postanalytical issues [7]. Among various factors that can affect Ki-67
immunohistochemistry, the type of biopsy may not be an important methodological issue and
samples from both core biopsy and surgical resection can be suitable [7].
However, when considering the growth of the clinical importance of Ki-67 and the practical
usefulness of neoadjuvant therapy, the type of specimens used to evaluate Ki-67 level can be
clinically significant. Several studies reported that the reliability of Ki-67 assessment was infe-
rior in biopsy samples compared to surgical specimens [8–10]. Fewer tumor cells are observed
in core biopsy specimens than in surgically-resected specimens [8]. In addition, tissue samples
from a core biopsy are usually obtained from near the central area of a tumor mass, even
though the peripheral areas of a tumor are more biologically active and highly proliferative
[11]. Furthermore, continuous efforts to test intra-institutional validity are critical because the
scoring methodology is not yet standardized [12].
The aim of this study was to investigate the distribution and correlation of Ki-67 expression
between preoperative biopsy and postoperative specimens. If some cases showed extremely dis-
cordant values between the two types of specimens, we aimed to determine which clinicopatho-
logical parameters were associated with discordant results for Ki-67 levels.
Patients and Methods
Patient selection
A total of 310 patients who underwent definitive surgery for breast carcinoma at the Severance
Hospital of Yonsei University College of Medicine, Seoul, Korea between January 2008 and
December 2013 were retrospectively selected. All patients in the study cohort had their Ki-67
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levels examined using paired preoperative biopsy and postsurgical specimens. Patients who
received neoadjuvant chemotherapy or did not undergo evaluation of both preoperative and
postoperative Ki-67 levels were excluded. This study was approved by the Institutional Review
Board of Severance Hospital, Seoul, Republic of Korea (IRB No. 4-2015-0680). Written
informed consent was waived and patient information was anonymized and deidentified prior
to analysis.
Clinicopathological characteristics
Clinicopathological data including expression of estrogen receptor (ER), progesterone receptor
(PR), and human epidermal growth factor receptor 2 (HER2) and Ki-67 levels were obtained
from the review of medical records and permanent pathology reports.
Tumors with1% nuclear-stained cells by immunohistochemistry using postsurgical speci-
mens were considered positive for ER and PR according to the ASCO/College of American
Pathologists (CAP) guidelines [13]. HER2 staining was scored as 0, 1+, 2+, or 3+ according to
ASCO/CAP guidelines [14]. In cases with a HER2 2+ result, fluorescence in situ hybridization
(FISH) was performed using a PathVysionHER2 DNA Probe Kit (Vysis, Downers Grove, IL,
USA) and HER2 gene amplification was defined as aHER2 gene/chromosome 17 copy number
ratio2.0 or a case with HER2 gene/chromosome 17 copy number ratio<2.0 but with average
HER2 copy number6.0 signals/cell according to ASCO/CAP guidelines [14]. HER2 was con-
sidered positive in cases with an immunohistochemistry score of 3+ or gene amplification by
FISH.
The Ki-67 levels were immunohistochemically measured in both biopsy and postsurgical
specimens using a primary MIB-1 antibody (Dako Denmark A/S, Glostrup, Denmark) by
established protocols of the Department of Pathology at our institution. Using a visual grading
system by a pathologist (J.S.K) who had specialized experience in breast pathology, the Ki-67
index of preoperative biopsy tissue samples was scored by counting the number of positively
stained nuclei and was expressed as a percentage of total tumor cells. Ki-67 levels of postopera-
tive surgical specimens were determined by calculating the percentages of strongly positive-
stained cells among 5,000 tumor cells in whole sections, which were mainly located at the
tumor periphery.
Statistical analysis
Differences between groups were evaluated using the chi-square test. Fisher’s exact test was
used when appropriate. The independent two-sample t-test was used for comparisons of
means for continuous numerical data. Comparison of Ki-67 levels between biopsy and surgical
specimens was performed with the Wilcoxon matched-pairs signed-rank test. In this study,
ΔKi-67 was calculated as postoperative Ki-67 levels minus preoperative Ki-67 levels. The outli-
ers of ΔKi-67 were defined as less than the lower quartile (Q1) of ΔKi-67 minus 1.5 × interquar-
tile range (IQR) or more than the upper quartile (Q3) plus 1.5 × IQR. A logistic regression
analysis was used to investigate significant risk factors associated with ΔKi-67 outliers. All sta-
tistical tests were two-sided, and P-values<0.05 were considered statistically significant. SPSS
software version 20.0 (IBM Inc., Armonk, NY, USA) was used for all analyses.
Results
The median Ki-67 levels from preoperative and postoperative specimens were 10% (IQR, 15;
range, 0%–80%) and 10% (IQR, 25; range, 0%–90%), respectively. Wilcoxon matched-pair
signed-rank testing revealed a significant association between preoperative and postoperative
Ki-67 levels (P<0.001). The mean ± standard deviation (SD) of the biopsy and surgical
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samples were 16.1% ± 15.8% and 21.2% ± 21.5%, respectively. Fig 1 shows the distribution and
a positive correlation of Ki-67 levels between the two types of specimens (Spearman’s
rho = 0.676; P<0.001). When a cutoff value of 14% was applied to define a low or high Ki-67
index, 131 of 177 (74.0%) patients with preoperative low Ki-67 were classified as having post-
operative low Ki-67, and 104 of 133 (78.2%) patients with preoperative high Ki-67 were defined
as having postoperative high Ki-67 (P<0.001).
The median value of ΔKi-67 was 2.0 (IQR, 12; range, −80 to 65). The mean difference in
proliferation values between biopsy and surgical specimens was 5.0 (SD, 15.8; 95% confidence
interval for the mean, 3.25–6.78). In the present study, the outliers of ΔKi-67 were determined
as−20 or28. The distribution and outlier range of ΔKi-67 levels are presented in Fig 2. Of
310 patients, 44 were categorized as outliers of ΔKi-67. There was no statistical difference in
clinicopathological characteristics except histologic grade between cases with ΔKi-67−20
(N = 15) and28 (N = 29). Grade III tumors were frequently categorized as ΔKi-6728
(P = 0.024).
Clinicopathological characteristics of patients classified as ΔKi-67 outliers compared to
those within the acceptable range of ΔKi-67 are shown in Table 1. Breast-conservation surgery
was performed in 171 patients, and the type of operation was not statistically different between
patients classified as ΔKi-67 outliers and those not classified as outliers. Patients younger than
35 years of age and those with tumor size>1 cm, grade III cancers, and ER-negative or PR-
negative tumors were significantly more likely to be categorized as ΔKi-67 outliers. Preopera-
tive biopsy tools, histologic type, axillary node status, and HER2 expression were not associated
with ΔKi-67 outlier status.
Risk factors for extremely discordant values of ΔKi-67 levels were investigated (Table 2).
Tumors>1 cm, PR-negative tumors, grade III cancers, ER-negative tumors, and age35 years
showed significantly higher odds ratios, in that order. When these parameters were entered
into multivariate logistic regression analysis, significant risk factors for outliers of ΔKi-67 were
found to be size>1 cm, negative PR, grade III, and age35 years. In our study cohort, 4 of 7
patients with all these risk factors were included among the ΔKi-67 outliers, and among these
patients, 3 showed discordantly higher Ki-67 levels in postsurgical specimens than in preopera-
tive biopsy samples.
Among 171 patients with hormone receptor-positive and HER2-negative tumors, breast
cancer subtypes were compared according to both preoperative and postoperative Ki-67 levels.
The cutoff point of Ki-67<14% was used for the discrimination of the luminal A subtype from
the highly proliferative luminal B, HER2-negative subtype. Concordant luminal A and luminal
B subtypes were classified in 97 (56.7%) and 28 (16.4%) patients, respectively, regardless of the
types of specimens. However, 30 (17.5%) patients whose tumors were categorized as luminal A
subtype according to preoperative Ki-67 levels discordantly changed to luminal B subtype
according to postoperative Ki-67 levels, and the opposite occurred in 16 (9.4%) patients.
According to the number of our risk factors (size>1 cm, negative PR, grade III, or age35
years), it was explored whether breast cancer subtypes were concordantly or discordantly clas-
sified (Table 3). Breast cancer subtype according to preoperative or postoperative Ki-67 levels
had discordantly changed in 46 (26.9%) patients. A significant proportion of patients with a
discordant subtype had1 of our risk factors (P = 0.004) and as the number of risk factors
increased, higher proportions of patients showed discordant breast cancer subtypes. Among
patients with2 risk factors, 17 (38.6%) cases were categorized into discordant subtypes. Of
these, 12 cases changed subtype from preoperative luminal A to postoperative luminal B and 5
changed subtype from preoperative luminal B to postoperative luminal A subtype.
Risk of Discordant Ki-67 Expression in Breast Cancers
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Discussion
In daily clinical practice, one of the major concerns regarding the categorization of breast can-
cer subtype using immunohistochemical markers is their reliability as a predictive factor, espe-
cially in relation to the use of chemotherapy for patients with luminal subtypes [15]. In the
First Korean Breast Cancer Treatment Consensus Conference 2014, half of the Korean panel-
ists chose the use of adjuvant chemotherapy for postmenopausal woman with T1c, node-nega-
tive, PR-positive, low Ki-67, and grade II disease [16]. Although semiquantitative
immunohistochemical expression of PR is also additive to the prognostic information for lumi-
nal subtypes [17,18], a current challenge is that the determination of a cutoff point for Ki-67, a
single level which has proven prognostic and predictive value, is difficult [15,19].
Clinicians should determine therapeutic modalities by the assessment of biomarkers using
preoperative core needle biopsy, postoperative specimens, or infrequently both. However, the
concordance rates of Ki-67 levels between core needle biopsy and postsurgical specimens have
not been much investigated. Moreover, a few studies have reported that the concordance rates
of Ki-67 between the two types of samples were lower than those for ER, PR, or HER2 expres-
sion [9,10,20,21]. However, the International Ki-67 in Breast Cancer Working Group com-
mented on the type of biopsy and stated that both core and whole sections were suitable,
although some data suggested that scores from whole sections might be higher than those from
core biopsies [7]. In the present study, a moderately positive linear relationship was shown
(coefficient = 0.676) and Ki-67 levels from surgical specimens were higher (median 2.0; mean
5.0) than those from preoperative biopsy specimens. This suggests that specimens from either
biopsy or surgery could be acceptable for the evaluation of Ki-67 but that in a certain group of
patients, it might be important to consider the type of specimen with particular caution.
The reason for discordant Ki-67 expression between two specimens may be associated with
various methodological issues including sampling problems or tumor heterogeneity [2,7].
Fig 1. Comparison of Ki-67 expression between preoperative biopsy and postoperative surgical
specimens. The solid line presents the best-fit correlation and the dotted lines show the 95% confidence
interval.
doi:10.1371/journal.pone.0151054.g001
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Because of its explorative and retrospective nature, although preanalytical variability was not
considered in the present study, we hypothesized that extremely discordant Ki-67 levels might
be associated with certain clinicopathological parameters and that it might be possible to rec-
ommend the evaluation of Ki-67 using both core biopsy and surgical specimens in patients
with certain risk factors. As there is no clear definition of extremely discordant values, we used
the outliers of ΔKi-67, which constituted 14.2% of the present study population.
Our study revealed that patients with extremely discordant Ki-67 levels between biopsy and
surgical specimens were more likely to have poor prognostic factors, which were larger tumor
size, negative PR, grade III, or younger age at diagnosis. In a population-based study of Ki-67
using surgical specimens, core biopsy, and tissue microarrays (TMAs), an increase in variability
of the difference in Ki-67 between whole sections and TMAs was detected as the Ki-67 average
of whole sections and TMAs increased [22]. However, Chen et al. [20] reported that there was
no difference in the concordance rate according to tumor stage and that in cases with ER-nega-
tive, PR-negative, or grade III tumors, the concordance rate of Ki-67 was rather higher. Differ-
ent study populations or methodologies may partly explain the different results between
studies. Importantly, our explorative study had limitations of interobserver and intraobserver
variability for evaluating Ki-67 labelling index since a pathologist (J.S.K) alone had interpreted
Ki-67 stained slides. Therefore, our analysis was not confirmative and further independent val-
idation with large samples is necessary.
The clinical implications of Ki-67 levels are of critical importance in hormone receptor-pos-
itive and HER2-negative tumors. It has been reported that 14%–21% of tumors classified as
luminal A subtype on core biopsy would be discordantly upgraded to luminal B on the basis of
Fig 2. Distribution ofΔKi-67 levels. ΔKi-67 is calculated by postoperative Ki-67 levels minus preoperative
Ki-67 levels. Q1, lower quartile; Q3, upper quartile; IQR, interquartile range.
doi:10.1371/journal.pone.0151054.g002
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surgical specimens [20,22]. Similarly, 17.5% of cases changed from luminal A on biopsy speci-
mens to luminal B on surgical specimens in the present study. Therefore, it has been suggested
that repeated Ki-67 assessment on both core needle and open excision biopsies should be per-
formed or that tissue-specific cutoff points of Ki-67 should be applied in clinical practice
[20,22]. In addition to prior studies, our results could clarify a subgroup of patients who require
particular clinical attention, which were those with1 of risk factors in our study. At present,
prognosis according to discordant subtypes was not investigated due to the relatively short fol-
low-up duration of the current study. However, our risk factors were traditional poor prognos-
tic factors; therefore, the benefit and harm of over- or under-treatment according to the
discordant classification of breast cancer subtypes should be calculated in the near future.
Table 1. Clinicopathological characteristics of patients classified asΔKi-67 outliers.
Acceptable (%, N = 266) Outlier (%, N = 44) P-value
Age (years)
Mean ± SD 49.8 ± 10.5 49.3 ± 12.2 0.798a
35 19 (70.4) 8 (29.6) 0.037b
>35 247 (87.3) 36 (12.7)
Preoperative biopsy tool
Core needle 227 (86.0) 37 (14.0) 0.829
VABB or incisional biopsy 39 (84.8) 7 (15.2)
Histologic type
Ductal 237 (85.6) 40 (14.4) >0.999b
Lobular or special 29 (87.9) 4 (12.1)
Tumor size
In situ or 1 cm 110 (95.7) 5 (4.3) <0.001
1–2 cm 99 (78.0) 28 (22.0)
>2 cm 57 (83.8) 11 (16.2)
Axillary lymph nodes
Negative 209 (85.3) 36 (14.7) 0.624
Positive 57 (87.7) 8 (12.3)
Grade
I/II 209 (91.7) 19 (8.3) <0.001
III 57 (69.5) 25 (30.5)
ER
Negative 58 (72.5) 22 (27.5) <0.001
Positive 208 (90.4) 22 (9.6)
PR
Negative 105 (75.5) 34 (24.5) <0.001
Positive 161 (94.2) 10 (5.8)
HER2
Negative 181 (84.6) 33 (15.4) 0.445
Equivocal 36 (92.3) 3 (7.7)
Positive 49 (86.0) 8 (14.0)
SD, standard deviation; VABB, Vacuum-assisted breast biopsy system; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal
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In conclusion, immunohistochemical Ki-67 expression demonstrated a substantial concor-
dance between preoperative biopsy and surgical specimens. Postoperative Ki-67 levels were
likely to be higher than preoperative values. Approximately one-seventh of patients showed
extremely discordant Ki-67 levels between the two types of specimens, and risk factors for the
Table 2. Logistic regression models of risk factors associated with classification as ΔKi-67 outlier.
Univariate Multivariatea
OR 95% CI P-value OR 95% CI P-value
Age (years)
>35 Ref Ref
35 2.889 1.178–7.084 0.020 3.290 1.121–9.659 0.030
Preoperative biopsy tool
Core needle Ref
VABB/incisional biopsy 1.101 0.458–2.645 0.829
Histologic type
Ductal Ref
Lobular or special 0.817 0.273–2.450 0.719
Tumor size
In situ or 1 cm Ref Ref
>1 cm 5.500 2.101–14.400 0.001 3.773 1.216–11.707 0.022
Axillary lymph nodes
Negative Ref
Positive 0.815 0.359–1.850 0.625
Grade
I/II Ref Ref
III 4.825 2.482–9.377 <0.001 2.496 1.093–5.698 0.030
ER
Positive Ref Ref
Negative 3.586 1.856–6.930 <0.001 0.914 0.354–2.356 0.852
PR
Positive Ref Ref
Negative 5.213 2.471–11.000 <0.001 3.529 1.394–8.935 0.008
HER2
Negative/equivocal Ref
Positive 0.984 0.431–2.249 0.970
OR, odds ratio; CI, conﬁdence interval; Ref, reference; VABB, Vacuum-assisted breast biopsy system; ER, estrogen receptor; PR, progesterone receptor;
HER2, human epidermal growth factor receptor 2.
aMultivariate analysis was conducted using variables that were statistically signiﬁcant in univariate analysis.
doi:10.1371/journal.pone.0151054.t002
Table 3. Association of number of risk factors with breast cancer subtype using preoperative and postoperative Ki-67 levels in 171 patients with
hormone receptor-positive and HER2-negative tumors.
Subtype Number of risk factors Total P-value
0 (N = 45) 1 (N = 82) 2 (N = 44)
Concordant 41 (91.1%) 57 (69.5%) 27 (61.4%) 125 (73.1%) 0.004
Discordant 4 (8.9%) 25 (30.5%) 17 (38.6%) 46 (26.9%)
HER2, human epidermal growth factor receptor 2
doi:10.1371/journal.pone.0151054.t003
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outlier values were associated with poor prognostic factors such as larger size, PR-negative
expression, grade III disease, and younger age at diagnosis. In patients with luminal HER2-ne-
gative tumors, the clinical classification of breast cancer subtype or decision making regarding
therapeutic modalities based on the routine pathologically assessed Ki-67 value should be
approached with caution considering the types of specimens and the patients’ clinicopathologi-
cal risk factors.
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